ArticleAging2019
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Flavonoid-modulated JAK-STAT signaling mitigates malignant transformation and drug resistance in breast tumors: A clinically relevant 3PM-guided innovation.Journal of advanced research · 2026Review
- SHP1 expression in tumor-associated dendritic cells drives immunoevasion via impairing CD8Oncogenesis · 2026Article
- Article
- A Novel Jak1 Gene Mutation in Invasive Breast Carcinoma.Journal of cellular and molecular medicine · 2025Article
- 7-Geranyloxycoumarin modulated metastatic potential of osteosarcoma cells via interaction with MMPs and JAK1/2.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- A molecular network analysis and in silico docking of beta-eudesmol, atractylodin and hinesol in patients with advance stage intrahepatic cholangiocarcinoma.Scientific reports · 2025Article
- An In Silico Approach to Uncover Selective JAK1 Inhibitors for Breast Cancer from Life Chemicals Database.Applied biochemistry and biotechnology · 2025Article
- CTDSPL2 promotes the progression of non-small lung cancer through PI3K/AKT signaling via JAK1.Cell death discovery · 2024Article
- Article
- JAK1 Is a Novel Target of Tumor- and Invasion-Suppressive microRNA 494-5p in Colorectal Cancer.Cancers · 2023Article
- Identification and validation of a novel necroptosis-related molecular signature to evaluate prognosis and immune features in breast cancer.Apoptosis : an international journal on programmed cell death · 2023Article
- High expression of CCDC69 is correlated with immunotherapy response and protective effects on breast cancer.BMC cancer · 2023Article
- The Effect of 5-aza,2'-deoxyCytidine (5 AZA CdR or Decitabine) on Extrinsic, Intrinsic, and JAK/STAT Pathways in Neuroblastoma and Glioblastoma Cells Lines.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Integrated analysis of single-cell and bulk transcriptome identifies a signature based on NK cell marker genes to predict prognosis and therapeutic response in clear cell renal cell carcinoma.Translational cancer research · 2023Article
- Identifying tumour microenvironment-related signature that correlates with prognosis and immunotherapy response in breast cancer.Scientific data · 2023Article
- Effect of N6-methyladenosine (m6A) regulator-related immunogenes on the prognosis and immune microenvironment of breast cancer.Translational cancer research · 2022Article
- circFCHO2 promotes gastric cancer progression by activating the JAK1/STAT3 pathway via sponging miR-194-5p.Cell cycle (Georgetown, Tex.) · 2022Article
- The effect of valproic acid on intrinsic, extrinsic, and JAK/STAT pathways in neuroblastoma and glioblastoma cell lines.Research in pharmaceutical sciences · 2022Article
- Circulating microRNA sequencing revealed miRNome patterns in hematology and oncology patients aiding the prognosis of invasive aspergillosis.Scientific reports · 2022Article
- Zinc Finger E-Box Binding Homeobox 2 as a Prognostic Biomarker in Various Cancers and Its Correlation with Infiltrating Immune Cells in Ovarian Cancer.Current issues in molecular biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical trials testing Janus kinase-1 (JAK1) inhibitors in cancers are under way. Whether the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.